Skip to main content
. 2023 Sep 6;13:14680. doi: 10.1038/s41598-023-40265-8

Table 7.

Prediction of QSAR models on drug compounds.

Compounds VEGFR2 model FGFR1 model
Experimental pIC50 Predicted pIC50 Prediction error Experimental pIC50 Predicted pIC50 Prediction error
2a 5.022 4.902  − 0.120 4.475 4.431  − 0.044
2b 4.073 4.223 0.150 4.254 4.192  − 0.062
2c 4.340 4.437 0.097 4.528 4.459  − 0.069
2d 4.701 4.763 0.062 4.378 4.408 0.030
2e 4.242 4.193  − 0.049 4.064 4.148 0.084
2f 4.422 4.343  − 0.079 4.186 4.170  − 0.016
4a 4.135 4.143 0.008 4.327 4.342 0.015
4b 4.822 4.560  − 0.262 4.202 4.208 0.006
4c 4.290 4.487 0.197 4.000 4.027 0.027
4d 4.584 4.569  − 0.015 4.106 4.083  − 0.023
AFATINIB 4.390 4.357  − 0.033 4.390 4.370  − 0.020
AXITINIB 4.640 4.643 0.003 4.640 4.672 0.032
DACOMITINIB 5.160 5.137  − 0.023 5.160 5.168 0.008
Doxorubicin 5.281 5.290 0.009 5.173 5.177 0.004
ENTRECTINIB 5.030 5.039 0.009 5.030 4.717  − 0.313
ERDAFITINIB 4.180 4.174  − 0.006 4.180 4.197 0.017
GEFITINIB 4.280 4.256  − 0.024 4.280 4.269  − 0.011
OLMUTINIB 5.100 4.761  − 0.339 5.100 4.714  − 0.386
OSIMERTINIB 4.510 4.538 0.028 4.510 4.491  − 0.019
ROCILETINIB 4.780 4.810 0.030 4.780 4.763  − 0.018
TUCATINIB 5.090 5.098 0.008 5.090 5.105 0.015